Does angioedema in patients with chronic spontaneous urticaria impact response to omalizumab?

The presence of angioedema, or deep skin swelling, in addition to hives (wheals) in patients with chronic spontaneous urticaria (CSU) can complicate disease management. There is evidence that omalizumab is effective for patients with CSU with angioedema, but the time to a clinically meaningful respo...

Full description

Bibliographic Details
Published in:	World Allergy Organization Journal
Main Authors:	Thomas B. Casale, MD, Benjamin Trzaskoma, MS, Michael Holden, MD, Jonathan A. Bernstein, MD, Marcus Maurer, MD
Format:	Article
Language:	English
Published:	Elsevier 2024-08-01
Subjects:	Angioedema Chronic spontaneous urticaria Omalizumab
Online Access:	http://www.sciencedirect.com/science/article/pii/S1939455124000747

Similar Items

Omalizumab for Patients with Chronic Spontaneous Urticaria: A Narrative Review of Current Status
by: Thomas B. Casale, et al.
Published: (2023-09-01)

Case Report: Omalizumab for Chronic Spontaneous Urticaria in Pregnancy
by: Shuang-Lu Liao, et al.
Published: (2021-03-01)

Multicentric and Observational Study of Omalizumab for Chronic Spontaneous Urticaria in Real-Life in Colombia
by: Elizabeth García-Gómez, et al.
Published: (2022-05-01)

Predictive model to differentiate chronic histaminergic angioedema and chronic spontaneous urticaria with angioedema
by: Ana Láinez-Nuez, MD, et al.
Published: (2024-08-01)

Retrospective analysis of the treatment of 61 cases of chronic spontaneous urticaria with omalizumab
by: Shanshan OU, et al.
Published: (2023-04-01)

Omalizumab's efficacy and safety against chronic spontaneous urticaria
by: Öner Özdemir
Published: (2023-08-01)

Position statement for the use of omalizumab in the management of chronic spontaneous urticaria in Indian patients
by: Kiran Godse, et al.
Published: (2016-01-01)

The challenges of chronic urticaria part 1: Epidemiology, immunopathogenesis, comorbidities, quality of life, and management
by: Mario Sánchez-Borges, et al.
Published: (2021-06-01)

Alopecia Areata after Omalizumab Treatment for Chronic Spontaneous Urticaria
by: Eli Magen
Published: (2019-07-01)

Effectiveness of transitioning from omalizumab to dupilumab in chronic spontaneous urticaria patients with inadequate response to omalizumab
by: Koremasa Hayama, M.D., Ph.D., et al.
Published: (2025-08-01)

Efficacy and safety of omalizumab against chronic spontaneous urticaria: Real-world study from China
by: Ao Wang, MD, et al.
Published: (2022-12-01)

Diagnostic testing for chronic spontaneous urticaria with or without angioedema: The do's, don't and maybe's
by: Jonathan A. Bernstein, MD, et al.
Published: (2025-07-01)

Omalizumab in the treatment of chronic spontaneous urticaria – literature review and own experience
by: Joanna Dawicka, et al.
Published: (2016-02-01)

Omalizumab for the management of refractory chronic spontaneous urticaria
by: P C Kathuria, et al.
Published: (2022-01-01)

Mapping the intellectual structure of the research of omalizumab in chronic spontaneous urticaria: A bibliometric analysis
by: Yuxu Yao, MD, et al.
Published: (2024-05-01)

Clinical observation of desloratadine combined with omalizumab in the treatment of chronic spontaneous urticaria
by: Zhiwei SHANG, et al.
Published: (2022-02-01)

Omalizumab withdrawal outcomes in chronic spontaneous urticaria are linked with baseline IgE and eosinophil levels
by: Ramit Maoz-Segal, MD, et al.
Published: (2024-05-01)

Cyclosporine for omalizumab-refractory chronic urticaria: a report of five cases
by: Anthony F. LaCava, et al.
Published: (2023-08-01)

Urticaria and Angioedema – More than just Skin Deep!
by: Jeanette Holtzhausen
Published: (2016-11-01)

COVID-19 infection in chronic spontaneous urticaria treated with omalizumab: two case reports
by: Angelo Massimiliano D'Erme, et al.
Published: (2023-08-01)

Ligelizumab improves angioedema, disease severity and quality-of-life in patients with chronic spontaneous urticaria
by: Martin Metz, MD, et al.
Published: (2022-11-01)

Urticaria crónica idiopática o urticaria espontánea y omalizumab. Revisión del tema a propósito de un caso
by: Giovanni Sedó Mejía, et al.
Published: (2014-05-01)

Efficacy of omalizumab treatment for patients with chronic idiopathic urticaria (CIU)/chronic spontaneous urticaria (CSU) in Taiwan
by: Che-Wen Yang, et al.
Published: (2017-12-01)

Omalizumab treatment can increase the serum levels of vitamin D in patients with chronic spontaneous urticaria
by: MENG Zhen, et al.
Published: (2025-03-01)

Different doses and courses of omalizumab for patients with chronic spontaneous urticaria: A systematic review with meta-analysis and trial sequential analysis
by: Haiyan Qin, MD, et al.
Published: (2024-04-01)

Disease control and quality of life in chronic spontaneous urticaria and recurrent angioedema are strongly linked, but not in all patients
by: Sophia Neisinger, et al.
Published: (2025-01-01)

Experience of long-term use of anti-IgE therapy in a patient with chronic spontaneous urticarial
by: E. A. Sobko, et al.
Published: (2022-04-01)

The impact of home treatment and self-administration of omalizumab on chronic urticaria
by: Anne Christine Wiuff, MBBS, et al.
Published: (2022-12-01)

Type I and type IIb autoimmune chronic spontaneous urticaria: Using common clinical tools for endotyping patients with CSU
by: Juliana A. Sella, MD, PhD, et al.
Published: (2023-11-01)

Efficiency of Adding Omalizumab to Standard Therapy for Children with Recurrent Spontaneous Urticaria: Comparative Observational Study
by: Vera G. Kalugina, et al.
Published: (2020-08-01)

Treatment of chronic spontaneous urticaria with a single dose of omalizumab: A study of four cases
by: Radhakrishnan Subramaniyan, et al.
Published: (2016-01-01)

Complete response to dupilumab in a patient with chronic spontaneous urticaria who did not tolerate omalizumab
by: Changhua Zhu, MD, et al.
Published: (2023-02-01)

Real-world safety and effectiveness of omalizumab in Japanese patients with chronic spontaneous urticaria: A post-marketing surveillance study
by: Michihiro Hide, et al.
Published: (2023-04-01)

The use of an urticaria control test for the evaluation of omalizumab treatment response in patients diagnosed with chronic urticaria
by: Burhan Engin, et al.
Published: (2020-12-01)

Omalizumab in Chronic Spontaneous Urticaria: A Real-World Study on Effectiveness, Safety and Predictors of Treatment Outcome
by: Chen J, et al.
Published: (2024-08-01)

Predictors of Early Response and Relapse in Chronic Spontaneous Urticaria Treated with Omalizumab: The Role of Age, Sex, Disease Duration, and UAS7
by: Mehmet Enes Güner, et al.
Published: (2025-10-01)

Predictors of response to omalizumab and relapse in chronic spontaneous Urticaria: a narrative review focusing on parameters available in routine clinical practice
by: Laura Mateu-Arrom, et al.
Published: (2025-10-01)

Long-term Omalizumab Therapy in Patients with Chronic Spontaneous Urticaria: Does it Increase the Risk of COVID-19?
by: Özge Kaya, et al.
Published: (2023-07-01)

Chronic spontaneous urticaria activity, impact and control as well as their changes are strongly linked, and these links are not affected by angioedema or comorbid inducible urticaria – Results from the validation of the Polish Urticaria Control Test
by: Zenon Brzoza, MD, PhD, et al.
Published: (2022-03-01)

A Practical Approach to Diagnosing and Managing Chronic Spontaneous Urticaria
by: Adam Friedman, et al.
Published: (2024-05-01)